Healthcare Industry News: Proteolix
News Release - April 4, 2011
Tobira Therapeutics Appoints Andrew Hindman President and Chief Executive OfficerMANALAPAN, N.J.--(Healthcare Sales & Marketing Network)-- Tobira Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for HIV infection, announced the appointment of Andrew Hindman as President and Chief Executive Officer, effective immediately.
“We are delighted to welcome Andrew, whose business development expertise and management accomplishments make him the ideal leader for Tobira at this pivotal time in our company’s growth,” said Laurent Fischer, M.D., Executive Chairman of the Board of Directors of Tobira. “As we advance the development of Cenicriviroc, Tobira’s dual CCR5/CCR2 antagonist for HIV infection, into Phase 2b clinical development, Andrew’s wealth of experience will enable our company to secure the partnerships required to bring this innovative HIV therapy to market.”
Mr. Hindman has served in various strategic and operational roles within the biopharmaceutical industry. Most recently as Senior Vice President, Corporate Development at Nodality Inc., a biotechnology company developing molecular diagnostics and personalized medicine approaches to drug development, he managed strategy and execution of collaborations with major pharmaceutical and biotech companies. Previously he was Vice President of Corporate Development at Onyx Pharmaceuticals where he led the acquisition of Proteolix, Inc. in 2009. Prior to joining Onyx, Mr. Hindman was with Gilead Sciences for more than 10 years, where he held a series of positions increasing in responsibility within corporate development, commercial operations and government affairs.
“Joining the Tobira team represents a unique opportunity,” Mr. Hindman said. “As we enter the third decade of battling the HIV epidemic, there continue to exist significant unmet needs for novel therapies with unique attributes that enable simpler treatment regimens and manage the long-term complications related to HIV infection. Cenicriviroc holds great potential to address these needs. I am highly motivated to lead Tobira’s next stage of growth as we advance the clinical development of Cenicriviroc. With the right team, the right compound and the right strategy, Tobira is well-poised to realize Cenicriviroc’s potential to become an integral component of future once-daily HIV treatment regimens, bringing important clinical benefits to patients with HIV/AIDS.”
About Tobira Therapeutics, Inc.
Tobira Therapeutics is a private biopharmaceutical company focused on developing and commercializing innovative antiviral compounds to treat HIV infection. Founded in 2006 by Eckard Weber, MD, a partner at the venture capital firm Domain Associates, and James Sapirstein, a strategic advisor to the Company, Tobira has assembled a highly experienced management team with decades of clinical and commercial development experience specifically in HIV/AIDS drug development. Cenicriviroc is a potent antagonist of CCR5, a co-receptor required for HIV infection, and CCR2, a co-receptor prominently involved in a number of metabolic and cardiovascular diseases. The Company will soon initiate its Phase 2b clinical study in individuals with HIV infection. For more information, please visit www.tobiratherapeutics.com.
Source: Tobira Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.